Indeed, CISD1 is significantly positively correlated with TMB and MSI in several cancers (Fig. 8A, B), indicating that patients with high expression of CISD1, together with high TMB and MSI, can benefit from immunotherapy, as a high TMB or MSI has been linked to better response to immune checkpoint inhibitors.62 Here, CISD1 is linked to cancer.